Skip to main content
Medexus Pharmaceuticals Inc. logo

Medexus Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · MDP ISIN · CA58410Q2036 LEI · 8945002TBEYY0HLH1M19 TSX Manufacturing
Open in API
Filings indexed 638 across all filing types
Latest filing 2021-02-08 Capital/Financing Update
Country CA Canada
Listing TSX MDP

About Medexus Pharmaceuticals Inc.

https://www.medexus.com/en_US

Medexus Pharmaceuticals, Inc. is an innovative specialty pharmaceutical company engaged in the development and commercialization of treatment solutions. The company utilizes a highly scalable North American business model, leveraging a fully integrated infrastructure encompassing commercial operations, supply chain, regulatory affairs, and a dedicated salesforce. Medexus focuses on building a portfolio of specialty and rare disease products across key therapeutic areas, including hematology, hematology-oncology, allergy, dermatology, and rheumatology. Its mission is to deliver quality healthcare products to patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
Preliminary short form prospectus – English.pdf
Capital/Financing Update Classification · 100% confidence The document is a preliminary short form prospectus for a public offering of securities by Medexus Pharmaceuticals Inc. It details the offering price, number of units, underwriting agreement, and terms of the securities being offered. The text includes legal disclaimers about regulatory approvals and restrictions on sales, typical of a prospectus. This document is related to capital raising and financing activities, specifically a new issue of securities. It is not an annual report, earnings release, or any other type of report but a financing disclosure document. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual prospectus, not just an announcement or a brief summary.
2021-02-08 English
Interim MD&A - French.pdf
Interim / Quarterly Report Classification · 95% confidence The document is titled "Rapport de gestion" which translates to "Management Report" and covers the quarter and half-year ended September 30, 2020. It includes detailed financial and operational information, discussion of acquisition impacts, COVID-19 effects, and forward-looking statements. The text references IFRS financial standards and contains substantive financial data and analysis for the interim period. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive analysis. The document is not merely an announcement or a certification, but a full management report with financial highlights and outlook. Therefore, the correct classification is IR with high confidence. H1 2021
2021-02-08 English
Interim financial statements/report – French.pdf
Interim / Quarterly Report Classification · 100% confidence The document contains detailed consolidated interim financial statements including balance sheets, income statements, statements of changes in equity, and cash flow statements for the quarter and semester ended September 30, 2020. It is explicitly labeled as "États financiers consolidés intermédiaires résumés (non audité)" which translates to "Condensed consolidated interim financial statements (unaudited)". The presence of actual financial data and the reporting period being less than a full fiscal year confirms this is an interim or quarterly report. The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. Therefore, the appropriate classification is Interim / Quarterly Report (IR). H1 2021
2021-02-08 English
Annual information form - French.pdf
Annual Report Classification · 95% confidence The document is titled "NOTICE ANNUELLE" for the fiscal year ended March 31, 2020, dated September 8, 2020. It contains a detailed table of contents including sections on company description, business development, intellectual property, risk factors, capital structure, management, audit committee, audit fees, legal proceedings, and other comprehensive corporate information. The content includes detailed narrative on the company's activities, financial transactions such as private placements, acquisitions, and capital raising, as well as governance and risk disclosures. The length is substantial (15,000 characters) and the document is not merely an announcement or a certification. The document is a comprehensive yearly report covering company activity and financial performance for the fiscal year, consistent with an Annual Report (10-K) filing. Therefore, the classification is Annual Report (10-K). FY 2020
2021-02-08 English
Notice of meeting - French.pdf
Regulatory Filings
2021-02-08 English
Other.pdf
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice of availability of proxy materials for a special meeting of securityholders, including instructions on how to access the full proxy materials and voting instructions. It does not contain the proxy materials themselves, nor does it include voting results or detailed meeting content. The document is short (3285 characters) and serves as an announcement directing shareholders to the full materials online or by request. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI) materials or a notice related to proxy materials. Given the content is a notice of availability of proxy materials for a special meeting, the best classification is Proxy Solicitation & Information Statement (PSI).
2021-02-08 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.